Share Price and Basic Stock Data
Last Updated: January 23, 2026, 6:23 pm
| PEG Ratio | 0.17 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fermenta Biotech Ltd operates in the pharmaceuticals industry, with a current market capitalization of ₹959 Cr and a share price of ₹326. The company’s revenue from operations has shown fluctuations, with sales reported at ₹349 Cr for FY 2023 and rising to ₹468 Cr for FY 2025. The trailing twelve months (TTM) sales stood at ₹563 Cr, indicating a positive growth trajectory. Quarterly sales figures also reflect variability, with a peak of ₹156 Cr recorded in December 2024, while the lowest point was ₹55 Cr in December 2022. This variability can be attributed to seasonal demand and operational challenges. The company’s operating profit margin (OPM) improved from 5% in FY 2023 to 25.90% in FY 2025, suggesting enhanced operational efficiency and cost management strategies. Overall, the revenue trends indicate a recovery and growth phase, supported by strategic initiatives in production and market expansion.
Profitability and Efficiency Metrics
Fermenta Biotech’s profitability metrics indicate a recovery from previous losses, with a net profit of ₹76 Cr reported for FY 2025, compared to a loss of ₹53 Cr in FY 2023. The company achieved an impressive return on equity (ROE) of 24.9% and return on capital employed (ROCE) of 23.0%, both significantly above typical industry averages, reflecting effective utilization of shareholders’ funds and capital. The interest coverage ratio (ICR) stood at 8.57x, showcasing the company’s ability to meet its interest obligations comfortably. The cash conversion cycle (CCC) of 189 days, however, indicates room for improvement in managing working capital, as it is longer than the industry average. Despite fluctuations in operating profit margins, which ranged from 5% to 25.90% over the past few years, the overall trend indicates an upward trajectory, suggesting improvements in cost management and operational efficiency.
Balance Sheet Strength and Financial Ratios
Fermenta Biotech’s balance sheet reflects a robust financial position, with total assets amounting to ₹614 Cr in FY 2025 and total liabilities at ₹548 Cr. The company’s reserves increased to ₹376 Cr, providing a solid equity base to support future growth initiatives. The total debt to equity ratio stood at 0.30, indicating a conservative leverage level, which is lower than many peers in the pharmaceuticals sector. The borrowing has declined from ₹220 Cr in FY 2023 to ₹115 Cr in FY 2025, demonstrating effective debt management. Additionally, the book value per share increased to ₹124.33, reflecting enhanced shareholder value. The current ratio of 1.58 and quick ratio of 0.99 suggest that the company is well-positioned to meet its short-term obligations, although the quick ratio indicates a tighter liquidity position, necessitating close monitoring.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fermenta Biotech reveals a strong promoter stake of 64.08%, which is a positive indicator of management confidence in the company’s future. The public shareholding stood at 34.75%, reflecting a diverse investor base. Foreign institutional investors hold a minimal stake of 0.02%, suggesting limited foreign interest, potentially due to market perceptions or operational challenges. The number of shareholders has seen a decline from 17,610 in December 2022 to 13,760 in September 2025, which may indicate a consolidation phase or a shift in investor sentiment. The low presence of institutional investors could be a concern, as it may impact liquidity and market perception. Overall, the high promoter holding indicates confidence in the company’s strategic direction, while the declining number of shareholders may require attention.
Outlook, Risks, and Final Insight
Looking forward, Fermenta Biotech has the potential for continued growth, supported by improving revenue trends and profitability metrics. The company’s strong ROE and ROCE indicate effective capital utilization, while a low debt-to-equity ratio signifies financial prudence. However, risks remain, including operational challenges reflected in the variability of sales and profitability, and the relatively high cash conversion cycle. Additionally, the low foreign institutional investment could limit broader market confidence. For a favorable outlook, Fermenta must focus on improving operational efficiencies, managing working capital effectively, and potentially attracting more institutional investors. If these factors align positively, the company could enhance its market position and shareholder value significantly in the coming years.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.9 | 197/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,463 Cr. | 318 | 479/192 | 71.7 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 43.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.7 | 43.4/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,525.73 Cr | 1,087.19 | 47.43 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 98 | 55 | 105 | 82 | 57 | 99 | 97 | 78 | 95 | 156 | 140 | 136 | 130 |
| Expenses | 95 | 65 | 86 | 72 | 71 | 74 | 92 | 77 | 76 | 103 | 103 | 108 | 104 |
| Operating Profit | 3 | -10 | 19 | 11 | -14 | 25 | 5 | 1 | 19 | 53 | 37 | 28 | 27 |
| OPM % | 3% | -18% | 18% | 13% | -24% | 25% | 6% | 1% | 20% | 34% | 26% | 21% | 20% |
| Other Income | 3 | -19 | -8 | 2 | -6 | 3 | 5 | 3 | 3 | 2 | 4 | 9 | 5 |
| Interest | 5 | 5 | 6 | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 | 3 |
| Depreciation | 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 |
| Profit before tax | -8 | -41 | -1 | 2 | -29 | 16 | 1 | -6 | 12 | 45 | 32 | 28 | 24 |
| Tax % | 6% | -8% | 373% | 0% | 0% | 38% | 885% | 0% | 6% | 16% | -4% | 23% | 25% |
| Net Profit | -8 | -38 | -5 | 2 | -29 | 10 | -7 | -6 | 11 | 38 | 33 | 22 | 18 |
| EPS in Rs | -2.75 | -12.70 | -1.40 | 0.62 | -9.70 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 | 6.42 |
Last Updated: December 27, 2025, 12:37 am
Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 130.00 Cr.. The value appears to be declining and may need further review. It has decreased from 136.00 Cr. (Jun 2025) to 130.00 Cr., marking a decrease of 6.00 Cr..
- For Expenses, as of Sep 2025, the value is 104.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 108.00 Cr. (Jun 2025) to 104.00 Cr., marking a decrease of 4.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 27.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Jun 2025) to 27.00 Cr., marking a decrease of 1.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Jun 2025) to 20.00%, marking a decrease of 1.00%.
- For Other Income, as of Sep 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Jun 2025) to 5.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Jun 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Jun 2025) to 24.00 Cr., marking a decrease of 4.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Jun 2025) to 25.00%, marking an increase of 2.00%.
- For Net Profit, as of Sep 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Jun 2025) to 18.00 Cr., marking a decrease of 4.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 6.42. The value appears to be declining and may need further review. It has decreased from 7.42 (Jun 2025) to 6.42, marking a decrease of 1.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:45 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 563 |
| Expenses | 113 | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 418 |
| Operating Profit | 26 | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 145 |
| OPM % | 19% | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 26% |
| Other Income | 3 | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 20 |
| Interest | 5 | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 13 |
| Depreciation | 10 | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 23 |
| Profit before tax | 14 | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 130 |
| Tax % | 24% | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% | |
| Net Profit | 10 | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 111 |
| EPS in Rs | 2.86 | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 | 38.06 |
| Dividend Payout % | 29% | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -90.00% | 100.00% | -550.00% | 611.11% | 154.35% | -48.72% | -28.33% | -65.12% | -453.33% | 54.72% | 416.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 190.00% | -650.00% | 1161.11% | -456.76% | -203.07% | 20.38% | -36.78% | -388.22% | 508.05% | 361.95% |
Fermenta Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 59% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 67% |
| 5 Years: | 7% |
| 3 Years: | 74% |
| TTM: | 532% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -3% |
| 3 Years: | 10% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| Last Year: | 25% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 15 |
| Reserves | 130 | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 376 |
| Borrowings | 65 | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | 112 |
| Other Liabilities | 61 | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | 149 |
| Total Liabilities | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 651 |
| Fixed Assets | 87 | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | 219 |
| CWIP | 36 | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 26 |
| Investments | 17 | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 118 | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 | 406 |
| Total Assets | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 651 |
Below is a detailed analysis of the balance sheet data for Fermenta Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
- For Reserves, as of Sep 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 348.00 Cr. (Mar 2025) to 376.00 Cr., marking an increase of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 112.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 115.00 Cr. (Mar 2025) to 112.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 149.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 137.00 Cr. (Mar 2025) to 149.00 Cr., marking an increase of 12.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 651.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 614.00 Cr. (Mar 2025) to 651.00 Cr., marking an increase of 37.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 219.00 Cr.. The value appears to be declining and may need further review. It has decreased from 227.00 Cr. (Mar 2025) to 219.00 Cr., marking a decrease of 8.00 Cr..
- For CWIP, as of Sep 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 406.00 Cr.. The value appears strong and on an upward trend. It has increased from 372.00 Cr. (Mar 2025) to 406.00 Cr., marking an increase of 34.00 Cr..
- For Total Assets, as of Sep 2025, the value is 651.00 Cr.. The value appears strong and on an upward trend. It has increased from 614.00 Cr. (Mar 2025) to 651.00 Cr., marking an increase of 37.00 Cr..
Notably, the Reserves (376.00 Cr.) exceed the Borrowings (112.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -39.00 | -55.00 | -68.00 | -75.00 | -80.00 | -53.00 | -158.00 | -149.00 | -177.00 | -202.00 | -111.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 |
| Inventory Days | 149 | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 306 |
| Days Payable | 120 | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 192 |
| Cash Conversion Cycle | 136 | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 189 |
| Working Capital Days | 9 | -61 | -49 | 33 | 54 | 43 | 70 | 54 | 67 | -18 | 9 | 40 |
| ROCE % | 9% | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | -0% | 3% | 23% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.77 |
| Diluted EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.69 |
| Cash EPS (Rs.) | 34.50 | 0.24 | -8.77 | 14.08 | 21.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Revenue From Operations / Share (Rs.) | 160.95 | 116.25 | 121.27 | 138.15 | 130.79 |
| PBDIT / Share (Rs.) | 41.69 | 13.62 | 8.88 | 24.12 | 31.17 |
| PBIT / Share (Rs.) | 33.39 | 5.06 | -0.90 | 15.26 | 24.13 |
| PBT / Share (Rs.) | 28.53 | -3.42 | -17.98 | 9.34 | 17.90 |
| Net Profit / Share (Rs.) | 26.19 | -8.31 | -18.56 | 5.22 | 14.74 |
| NP After MI And SOA / Share (Rs.) | 26.35 | -7.99 | -17.85 | 5.35 | 15.77 |
| PBDIT Margin (%) | 25.90 | 11.71 | 7.32 | 17.46 | 23.83 |
| PBIT Margin (%) | 20.74 | 4.34 | -0.74 | 11.04 | 18.44 |
| PBT Margin (%) | 17.72 | -2.94 | -14.82 | 6.76 | 13.68 |
| Net Profit Margin (%) | 16.27 | -7.15 | -15.30 | 3.77 | 11.27 |
| NP After MI And SOA Margin (%) | 16.37 | -6.86 | -14.71 | 3.87 | 12.06 |
| Return on Networth / Equity (%) | 21.19 | -7.98 | -16.36 | 4.15 | 12.62 |
| Return on Capital Employeed (%) | 24.19 | 3.89 | -0.61 | 8.81 | 14.56 |
| Return On Assets (%) | 12.50 | -4.20 | -8.09 | 2.18 | 6.62 |
| Long Term Debt / Equity (X) | 0.04 | 0.14 | 0.26 | 0.30 | 0.30 |
| Total Debt / Equity (X) | 0.30 | 0.45 | 0.68 | 0.63 | 0.57 |
| Asset Turnover Ratio (%) | 0.80 | 0.56 | 0.52 | 0.55 | 0.57 |
| Current Ratio (X) | 1.58 | 1.40 | 1.21 | 1.52 | 1.48 |
| Quick Ratio (X) | 0.99 | 0.89 | 0.58 | 0.74 | 0.70 |
| Inventory Turnover Ratio (X) | 4.45 | 0.70 | 0.77 | 0.91 | 1.06 |
| Dividend Payout Ratio (NP) (%) | 4.69 | -15.65 | -7.00 | 46.68 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 3.57 | 217.49 | -15.50 | 17.58 | 0.00 |
| Earning Retention Ratio (%) | 95.31 | 115.65 | 107.00 | 53.32 | 0.00 |
| Cash Earning Retention Ratio (%) | 96.43 | -117.49 | 115.50 | 82.42 | 0.00 |
| Interest Coverage Ratio (X) | 8.57 | 2.31 | 1.23 | 4.07 | 5.00 |
| Interest Coverage Ratio (Post Tax) (X) | 6.38 | 0.02 | -0.20 | 1.88 | 3.37 |
| Enterprise Value (Cr.) | 831.46 | 505.89 | 464.45 | 795.24 | 883.96 |
| EV / Net Operating Revenue (X) | 1.77 | 1.51 | 1.33 | 2.00 | 2.34 |
| EV / EBITDA (X) | 6.84 | 12.87 | 18.12 | 11.43 | 9.83 |
| MarketCap / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| Retention Ratios (%) | 95.30 | 115.65 | 107.00 | 53.31 | 0.00 |
| Price / BV (X) | 2.20 | 1.51 | 0.98 | 1.59 | 2.00 |
| Price / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| EarningsYield | 0.09 | -0.05 | -0.16 | 0.02 | 0.06 |
After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Cash EPS (Rs.), as of Mar 25, the value is 34.50. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 34.50, marking an increase of 34.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 160.95. It has increased from 116.25 (Mar 24) to 160.95, marking an increase of 44.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 41.69. This value is within the healthy range. It has increased from 13.62 (Mar 24) to 41.69, marking an increase of 28.07.
- For PBIT / Share (Rs.), as of Mar 25, the value is 33.39. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 33.39, marking an increase of 28.33.
- For PBT / Share (Rs.), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from -3.42 (Mar 24) to 28.53, marking an increase of 31.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 26.19. This value is within the healthy range. It has increased from -8.31 (Mar 24) to 26.19, marking an increase of 34.50.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For PBDIT Margin (%), as of Mar 25, the value is 25.90. This value is within the healthy range. It has increased from 11.71 (Mar 24) to 25.90, marking an increase of 14.19.
- For PBIT Margin (%), as of Mar 25, the value is 20.74. This value exceeds the healthy maximum of 20. It has increased from 4.34 (Mar 24) to 20.74, marking an increase of 16.40.
- For PBT Margin (%), as of Mar 25, the value is 17.72. This value is within the healthy range. It has increased from -2.94 (Mar 24) to 17.72, marking an increase of 20.66.
- For Net Profit Margin (%), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 10. It has increased from -7.15 (Mar 24) to 16.27, marking an increase of 23.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.37. This value is within the healthy range. It has increased from -6.86 (Mar 24) to 16.37, marking an increase of 23.23.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.19. This value is within the healthy range. It has increased from -7.98 (Mar 24) to 21.19, marking an increase of 29.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 24.19. This value is within the healthy range. It has increased from 3.89 (Mar 24) to 24.19, marking an increase of 20.30.
- For Return On Assets (%), as of Mar 25, the value is 12.50. This value is within the healthy range. It has increased from -4.20 (Mar 24) to 12.50, marking an increase of 16.70.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 24) to 0.04, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.45 (Mar 24) to 0.30, marking a decrease of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has increased from 0.56 (Mar 24) to 0.80, marking an increase of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 1.58. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.58, marking an increase of 0.18.
- For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.99, marking an increase of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.45. This value is within the healthy range. It has increased from 0.70 (Mar 24) to 4.45, marking an increase of 3.75.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.69. This value is below the healthy minimum of 20. It has increased from -15.65 (Mar 24) to 4.69, marking an increase of 20.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.57. This value is below the healthy minimum of 20. It has decreased from 217.49 (Mar 24) to 3.57, marking a decrease of 213.92.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.31. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.31, marking a decrease of 20.34.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.43. This value exceeds the healthy maximum of 70. It has increased from -117.49 (Mar 24) to 96.43, marking an increase of 213.92.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 8.57, marking an increase of 6.26.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 6.38, marking an increase of 6.36.
- For Enterprise Value (Cr.), as of Mar 25, the value is 831.46. It has increased from 505.89 (Mar 24) to 831.46, marking an increase of 325.57.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.77, marking an increase of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 6.84. This value is within the healthy range. It has decreased from 12.87 (Mar 24) to 6.84, marking a decrease of 6.03.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For Retention Ratios (%), as of Mar 25, the value is 95.30. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.30, marking a decrease of 20.35.
- For Price / BV (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 2.20, marking an increase of 0.69.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.09, marking an increase of 0.14.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fermenta Biotech Ltd:
- Net Profit Margin: 16.27%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 24.19% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.19% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.99
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 8.18 (Industry average Stock P/E: 47.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.27%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-1501, Thane One, DIL Complex, Thane Maharashtra 400610 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep M Chandan | Chairman & Ind.Dire (Non-Exe) |
| Mr. Krishna Datla | Exe.Vice Chairman & Whole Time Director |
| Mr. Prashant Nagre | Managing Director |
| Mr. Satish Varma | Executive Director |
| Ms. Anupama Datla Desai | Executive Director |
| Ms. Rajeshwari Datla | Non Executive Director |
| Mr. Pramod Kasat | Ind. Non-Executive Director |
| Ms. Rajashri Ojha | Ind. Non-Executive Director |
| Mr. Ramanand Mundkur | Independent Director |
FAQ
What is the intrinsic value of Fermenta Biotech Ltd?
Fermenta Biotech Ltd's intrinsic value (as of 26 January 2026) is ₹324.65 which is 4.39% higher the current market price of ₹311.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹916 Cr. market cap, FY2025-2026 high/low of ₹449/219, reserves of ₹376 Cr, and liabilities of ₹651 Cr.
What is the Market Cap of Fermenta Biotech Ltd?
The Market Cap of Fermenta Biotech Ltd is 916 Cr..
What is the current Stock Price of Fermenta Biotech Ltd as on 26 January 2026?
The current stock price of Fermenta Biotech Ltd as on 26 January 2026 is ₹311.
What is the High / Low of Fermenta Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fermenta Biotech Ltd stocks is ₹449/219.
What is the Stock P/E of Fermenta Biotech Ltd?
The Stock P/E of Fermenta Biotech Ltd is 8.18.
What is the Book Value of Fermenta Biotech Ltd?
The Book Value of Fermenta Biotech Ltd is 133.
What is the Dividend Yield of Fermenta Biotech Ltd?
The Dividend Yield of Fermenta Biotech Ltd is 0.80 %.
What is the ROCE of Fermenta Biotech Ltd?
The ROCE of Fermenta Biotech Ltd is 23.0 %.
What is the ROE of Fermenta Biotech Ltd?
The ROE of Fermenta Biotech Ltd is 24.9 %.
What is the Face Value of Fermenta Biotech Ltd?
The Face Value of Fermenta Biotech Ltd is 5.00.